SCHEMBL2213858

SCHEMBL2213858

CS(=O)(=O)c1nc(-c2cccc(Br)c2)cc2ccnn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.42
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
HCRTR1 O43613 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TP53 P04637 1/20 0.39
PTGS2 P35354 2/20 0.38
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HK1 P19367 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
CDK1 P06493 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209540 0.86 BPTF (0.36) RAB9ATP53PTGS2MAPTSMN1; SMN2
SCHEMBL2876715 0.86 PLCG1 (0.43) RAB9ANPC1TP53PTGS2MAPT
SCHEMBL2214081 0.83 SCD (0.42) CDK2RAB9ATP53PTGS2MAPT
SCHEMBL2209412 0.80 ABL1 (0.41) RAB9ATP53MAPTSMN1; SMN2ALDH1A1
SCHEMBL2211402 0.78 BPTF (0.37) CDK2RAB9ATP53PTGS2SMN1; SMN2
SCHEMBL2882567 0.78 RAD52 (0.47) RAB9ANPC1TP53MAPTSMN1; SMN2
SCHEMBL2213701 0.77 CDK2 (0.44) CDK2RAB9ANPC1HCRTR1CASP3
SCHEMBL2211383 0.76 CYP2C9 (0.45) RAB9ANPC1CASP3SENP8SENP7
SCHEMBL2881702 0.75 KDM4E (0.45) RAB9ANPC1TP53PTGS2MAPT
SCHEMBL2882272 0.74 FYN (0.48) RAB9ANPC1TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 CDK2 8/4885RAB9A 3213/4885NPC1 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.